|Other names||Isoniazid regimen with rifapentine|
|Side effects||Liver problems, allergic reactions|
Isoniazid/rifapentine is a combination medication used to treat tuberculosis. Specifically it is used once a week for three months for latent TB. It decreases risks of progress from infection to disease by 60 to 90%. It is taken by mouth once per week for 12 weeks.
Side effects may include liver problems, low platelets, and allergic reactions. Use is not recommended in pregnancy. There are many potential medication interactions. It is a combination of isoniazid and rifapentine. Isoniazid works in part by disrupting the formation of the bacteria's cell wall. Rifapentine is in the rifamycin family of medication and works by blocking DNA-dependent RNA polymerase.
The combination was added to the World Health Organization's List of Essential Medicines in 2021. The individual medications were previously included in 2015 and 1977. As of 2022 the individual medications costs about 73 USD per course of treatment in the developing world.
Each pill contains 300 mg of isoniazid and 300 mg rifapentine.
- "Use of rifapentine and isoniazid combination therapy for the treatment of latent tuberculosis infection in Ontario" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 1 December 2022.
- "Rifapentine + isoniazid 2021 Expert Committee on Selection and Use of Essential Medicines Application review" (PDF). Archived (PDF) from the original on 2 December 2022. Retrieved 2 December 2022.
- "Latent TB Infection Medicine- Isoniazid & Rifapentine | TB | CDC". www.cdc.gov. 15 August 2022. Archived from the original on 27 June 2022. Retrieved 1 December 2022.
- "Isoniazid". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- "Rifapentine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.